Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 12/20 | 0.79 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9090117 | 0.84 | ESR1 (0.82) | ESR1ESR2HRH4 | |
| SCHEMBL27333247 | 0.81 | ESR1 (0.53) | ESR1ESR2HRH4ALDH1A1L3MBTL1 | |
| SCHEMBL20476323 | 0.79 | MAPT (0.50) | ESR1ALDH1A1KMT2AMAPTMEN1 | |
| SCHEMBL8541019 | 0.78 | ESR1 (0.58) | ESR1ESR2HRH4ALDH1A1 | |
| SCHEMBL15585264 | 0.76 | TLR8 (0.51) | ESR1ESR2ALDH1A1L3MBTL1KMT2A | |
| SCHEMBL11779005 | 0.76 | ESR1 (0.46) | ESR1ALDH1A1L3MBTL1KMT2AMAPT | |
| SCHEMBL11779958 | 0.76 | ESR1 (0.46) | ESR1ALDH1A1L3MBTL1KMT2AMAPT | |
| SCHEMBL20476318 | 0.76 | ALDH1A1 (0.51) | ESR1HRH4ALDH1A1L3MBTL1KMT2A | |
| SCHEMBL22228324 | 0.75 | ALDH1A1 (0.54) | ESR1HRH4ALDH1A1KMT2AMEN1 | |
| SCHEMBL9884955 | 0.75 | SMN1; SMN2 (0.49) | ESR1ALDH1A1KMT2AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4606806-A1 | TRANSITION METAL COMPOUND AND CATALYST COMPOSITION COMPRISING THE SAME | LG CHEM, LTD. (KR) | 2025-08-27 | — | — | EP | disclosed |
| WO-2024177286-A1 | TRANSITION METAL COMPOUND AND CATALYST COMPOSITION COMPRISING SAME | 주식회사 엘지화학 | 2024-08-29 | — | — | WO | disclosed |
| US-8962834-B2 | Modulators of amyloid beta | HOFFMANN-LA ROCHE INC. (US) | 2015-02-24 | — | — | US | disclosed |
| EP-2257541-B1 | MODULATORS FOR AMYLOID BETA | HOFFMANN LA ROCHE (CH) | 2013-08-14 | — | — | EP | disclosed |
| US-20130190302-A1 | MODULATORS OF AMYLOID BETA | HOFFMANN-LA ROCHE INC. (US) | 2013-07-25 | — | — | US | disclosed |
| CN-101952275-A | Modulators for amyloid beta | HOFFMANN LA ROCHE | 2011-01-19 | — | — | CN | disclosed |
| EP-2257541-A1 | MODULATORS FOR AMYLOID BETA | F. Hoffmann-La Roche AG (CH) | 2010-12-08 | — | — | EP | disclosed |
| US-20090215759-A1 | MODULATORS FOR AMYLOID BETA | HOFFMANN-LA ROCHE, INC. | 2009-08-27 | — | — | US | disclosed |
| WO-2009103652-A1 | MODULATORS FOR AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215759-A1 | MODULATORS FOR AMYLOID BETA | APP, PSEN1, APOB | ESR1 4876/4885ESR2 4000/4885HRH4 2013/4885 |
| US-20130190302-A1 | MODULATORS OF AMYLOID BETA | APP, PSEN1, APOB | ESR1 4875/4885ESR2 4017/4885HRH4 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.